📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Prime Focus' BRAHMA AI Partners with Google Cloud to Scale Digital Humans
BRAHMA AI, an enterprise AI content platform backed by Prime Focus Limited, has entered a multi-year strategic partnership with Google Cloud. The collaboration aims to scale high-fidelity, interactive digital humans (ATMANS) using Google Cloud's generative AI models and infrastructure. This partnership targets a global AI content market projected to exceed $130 billion by 2030. By leveraging BRAHMA AI's Hollywood-grade technology, which has contributed to 8 Academy Award-winning films, the company seeks to expand its reach into healthcare, sports, and advertising sectors.
Key Highlights
Multi-year strategic partnership with Google Cloud to deploy interactive digital humans globally.
Targets a total addressable market (TAM) for AI content estimated to exceed $130 billion by 2030.
Utilizes technology from BRAHMA AI that has won 8 Academy Awards for Best Visual Effects.
Joint go-to-market approach combining Google Cloud's infrastructure with BRAHMA AI's content platform.
Focuses on high-fidelity, multilingual audio and hyper-personalized digital likenesses for enterprises.
💼 Action for Investors
Investors should view this as a significant validation of Prime Focus's AI capabilities and a strategic move to diversify revenue beyond traditional post-production. Monitor the partnership's ability to convert this technology into scalable enterprise contracts over the next few quarters.
Dr. Reddy's Wins Court Approval to Export Semaglutide to Non-Patent Markets
Dr. Reddy's Laboratories has clarified that the Delhi High Court has ruled in its favor regarding the manufacture and export of Semaglutide. The Division Bench upheld a previous order from March 09, 2026, which allows the company to produce the drug in India for export to countries where Novo Nordisk does not hold patent registrations. This decision follows a legal challenge by Novo Nordisk, which sought an interim injunction against Dr. Reddy's. While the matter remains sub-judice, this ruling provides a significant pathway for Dr. Reddy's to enter the high-growth GLP-1 market internationally.
Key Highlights
Delhi High Court Division Bench upheld the March 09, 2026, order allowing Semaglutide production.
Permission granted to export Semaglutide to international markets where Novo Nordisk lacks patent protection.
Court refused to grant an interim injunction requested by Danish pharmaceutical firm Novo Nordisk.
The ruling pertains to Semaglutide-containing products, a key category in diabetes and weight management.
Dr. Reddy's clarified that while the matter is sub-judice, the current ruling supports their manufacturing plans.
💼 Action for Investors
Investors should monitor Dr. Reddy's progress in scaling Semaglutide exports to non-patent jurisdictions as it represents a major growth opportunity. The stock may see positive sentiment following this legal clearance for a high-demand product.
Adani Infra Completes Acquisition of Punj Lloyd for INR 281.10 Crores
Adani Infra (India) Limited has successfully completed the acquisition of Punj Lloyd Limited on a going concern basis under the Insolvency and Bankruptcy Code liquidation process. The total sale consideration of INR 281.10 crores has been paid in full as of March 10, 2026. As part of the deal, Adani Infra has assumed liabilities for bank guarantees, including 10% of disputed and 25% of ongoing project guarantees. This marks the formal transfer of the company to the Adani Group, potentially reviving the distressed engineering firm.
Key Highlights
Adani Infra (India) Limited paid a total sale consideration of INR 281.10 crores for the acquisition.
The acquisition was finalized on a going concern basis following the NCLT order dated February 12, 2026.
Adani Infra assumed liability for 10% of disputed bank guarantees and 25% of ongoing project bank guarantees.
The Sale Certificate was executed on March 10, 2026, which is also the official Transfer Date.
The acquisition follows the 14th round of e-auction conducted under the liquidation process.
💼 Action for Investors
While the acquisition ensures the company's survival, equity shareholders should be cautious as IBC-led acquisitions often involve significant capital restructuring or delisting. Investors should wait for specific details regarding the treatment of existing equity shares under the new ownership.
NLC India Secures AAA Rating for ₹1000 Cr ECB; Term Loan Rating Reaffirmed
Acuite Ratings & Research Limited has assigned a top-tier 'ACUITE AAA | Stable' rating to NLC India's new ₹1,000 crore External Commercial Borrowing (ECB). Furthermore, the agency reaffirmed the 'ACUITE AAA | Stable' rating for the company's ₹950 crore Term Loan. These ratings reflect the company's strong credit profile and its strategic importance as a 'Navratna' Government of India Enterprise. The stable outlook indicates a high degree of safety regarding timely servicing of financial obligations.
Key Highlights
Acuite Ratings assigned a new 'ACUITE AAA
Stable' rating for ₹1,000 crore External Commercial Borrowing (ECB).
Reaffirmed 'ACUITE AAA
Stable' rating for an existing ₹950 crore Term Loan.
Total debt instruments covered in this rating action amount to ₹1,950 crore.
The AAA rating signifies the highest level of creditworthiness and lowest credit risk for lenders.
💼 Action for Investors
The assignment of the highest credit rating confirms NLC India's ability to raise low-cost capital, which is crucial for its capital-intensive power and mining projects. Investors should remain positive on the stock as this reinforces the company's financial stability and operational strength.
NCLT Approves Merger of Asian Paints (Polymers) with Asian Paints Ltd
The National Company Law Tribunal (NCLT), Mumbai, has sanctioned the Scheme of Amalgamation of Asian Paints (Polymers) Private Limited, a wholly-owned subsidiary, with its parent company, Asian Paints Limited. The merger is effective from the appointed date of April 1, 2025, and aims to simplify the group structure and reduce administrative costs. Despite the subsidiary's substantial authorized capital of INR 1,300 crore, the company has explicitly stated that there is no material impact on its consolidated financials. This move is primarily a corporate restructuring to enhance operational efficiency and consolidate resources.
Key Highlights
NCLT Mumbai Bench sanctioned the merger scheme via an order dated March 10, 2026.
The merger involves a wholly-owned subsidiary with an authorized capital of INR 1,300 crore.
The appointed date for the scheme of amalgamation is set retrospectively as April 1, 2025.
Management confirms the restructuring will have no material impact on the company's financials.
The consolidation is expected to reduce legal and regulatory compliance burdens and administrative overheads.
💼 Action for Investors
Investors should note this as a routine internal consolidation that simplifies the corporate structure without affecting the company's valuation or earnings. No immediate portfolio action is required based on this administrative update.
Themis Medicare Revises Preferential Issue Price Upward to Rs 102.87 per Warrant
Themis Medicare has issued a corrigendum to its postal ballot notice, increasing the issue price of 45,95,795 convertible warrants from Rs 100 to Rs 102.87 per warrant. This adjustment follows observations from the National Stock Exchange (NSE) regarding the pricing formula under SEBI (ICDR) Regulations. The total fundraise amount has consequently increased from approximately Rs 45.96 crore to Rs 47.28 crore. The warrants are being issued on a preferential basis to the promoter group entity, Vividhmargi Investments Private Limited.
Key Highlights
Issue price revised from Rs 100 to Rs 102.87 per warrant based on NSE regulatory observations
Total aggregate fundraise increased by approximately Rs 1.32 crore to a total of Rs 47.28 crore
Issuance of 45,95,795 warrants to promoter group company Vividhmargi Investments Private Limited
Upfront payment of 25% revised to Rs 11.82 crore, with the remaining 75% due upon warrant exercise
Shareholders who already voted have until March 27, 2026, to modify their votes in light of the changes
💼 Action for Investors
Investors should view the upward revision of the issue price as a positive development as it reduces dilution impact slightly compared to the previous price. Monitor the final approval and subsequent utilization of these funds for the company's growth initiatives.
Adani Infra Completes Acquisition of Punj Lloyd for INR 281.10 Crore
Adani Infra (India) Limited has finalized the acquisition of Punj Lloyd Limited on a going concern basis following the insolvency resolution process. The successful bidder has paid the full sale consideration of INR 281.10 crore as per the NCLT order. Additionally, Adani Infra has assumed specific liabilities related to bank guarantees for ongoing and disputed projects. The official transfer of the company was completed on March 10, 2026, via a sale certificate.
Key Highlights
Total sale consideration of INR 281.10 crore paid by Adani Infra (India) Limited.
Acquisition executed on a going concern basis under the IBC liquidation process.
Official transfer date confirmed as March 10, 2026, following NCLT approval.
Adani Infra assumed 10% liability for disputed and 25% for ongoing project bank guarantees.
💼 Action for Investors
Existing shareholders should exercise caution as insolvency resolutions often involve significant equity dilution or wipeouts. Monitor upcoming disclosures regarding the treatment of existing equity and the new management's turnaround plan.
Themis Medicare Revises Preferential Issue Price to Rs 102.87 per Warrant
Themis Medicare's Preferential Issue Committee has revised the pricing for its upcoming warrant issuance to Vividhmargi Investments Private Limited. The issue price has been increased from Rs 100 to Rs 102.87 per convertible equity warrant to comply with SEBI (ICDR) pricing regulations. The company intends to issue up to 45,95,795 warrants, which represents approximately 4.99% of the total shareholding. This capital infusion is subject to shareholder and stock exchange approvals.
Key Highlights
Revised issue price of convertible equity warrants to Rs 102.87 from the previous Rs 100 per warrant
Proposed issuance of up to 45,95,795 warrants to a single investor, Vividhmargi Investments Private Limited
The total issuance represents up to 4.99% of the company's total shareholding post-conversion
Pricing adjustment follows a modified certificate from practicing company secretaries to meet SEBI Regulation 164 requirements
Approved a corrigendum to the Postal Ballot Notice dated February 25, 2026, to reflect these changes
💼 Action for Investors
Investors should note the minor upward revision in the entry price for the new investor, which is slightly less dilutive than the previous terms. Monitor the upcoming shareholder vote and the company's stated purpose for utilizing the raised capital.
Adani Infra Acquires Punj Lloyd for INR 281.10 Cr on Going Concern Basis
Adani Infra (India) Limited has successfully completed the acquisition of Punj Lloyd Limited on a going concern basis through the liquidation process under the Insolvency and Bankruptcy Code. The total sale consideration of INR 281.10 crores has been paid in full, and the Sale Certificate was executed on March 10, 2026. This acquisition follows the 14th round of e-auction and subsequent approval by the NCLT. The deal also involves the assumption of specific liabilities regarding bank guarantees by the successful bidder.
Key Highlights
Total sale consideration of INR 281.10 crores paid by Adani Infra (India) Limited
Acquisition executed on a going concern basis with the official Transfer Date of March 10, 2026
Successful bidder assumed 10% liability for disputed bank guarantees and 25% for ongoing project bank guarantees
Resolution follows the NCLT Principal Bench order dated February 12, 2026, approving the Acquisition Plan
💼 Action for Investors
Investors should remain cautious as insolvency resolutions typically result in significant equity dilution or delisting for existing shareholders. Monitor upcoming disclosures regarding the treatment of existing equity and the company's future listing status under Adani Group management.
Piramal Finance Receives USD 148.1 Million from Piramal Imaging SA Divestment
Piramal Finance Limited has received a substantial cash inflow of USD 148.099 million as deferred consideration for the divestment of its step-down subsidiary, Piramal Imaging SA. This payment is part of a transaction with Alliance Medical Acquisitionco Limited that dates back to 2018. The company remains eligible for further earnouts in subsequent years, with the total consideration capped at USD 200 million. Management intends to utilize these proceeds to further strengthen the company's balance sheet and liquidity.
Key Highlights
Received USD 148.099 million on March 10, 2026, as contingent deferred consideration.
Total potential earnouts from the Imaging Group divestment are capped at USD 200 million.
The divestment involves the step-down subsidiary Piramal Imaging SA to Alliance Medical Acquisitionco Limited.
Proceeds will be strategically used to strengthen the company's balance sheet.
Future earnouts are subject to eligible profits and performance of the Imaging Group.
💼 Action for Investors
This is a significant liquidity event that bolsters the company's capital base without equity dilution. Investors should view this as a positive development for the company's credit profile and growth capacity.
TNPETRO Revises Project Costs to ₹602 Cr and Announces New ₹90 Cr Downstream Units
Tamilnadu PetroProducts Limited (TNPETRO) has announced a significant revision in its ongoing project costs and a new expansion plan. The cost for the LAB plant expansion has been revised from ₹310 crore to ₹365 crore, while the HCD plant expansion cost increased from ₹214 crore to ₹237 crore due to forex fluctuations and cost escalations. Additionally, the board approved ₹90 crore for setting up two new downstream units in the HCD plant, expected to be completed within 18 months. The total capital commitment for these projects now exceeds ₹690 crore, funded via internal accruals and debt.
Key Highlights
LAB plant expansion cost increased by 17.7% from ₹310 crore to ₹365 crore.
HCD plant expansion cost revised from ₹214 crore to ₹237 crore citing forex and time-related escalations.
New ₹90 crore investment approved for two downstream units in the HCD plant with an 18-month execution timeline.
Total project outlay across these updates stands at approximately ₹692 crore.
Funding strategy involves a mix of internal accruals and borrowings based on future business conditions.
💼 Action for Investors
Investors should monitor the impact of the ₹78 crore cost overrun on the company's margins and debt levels. While the expansion into downstream units is positive for long-term value addition, the delay and cost escalation in existing projects warrant a cautious approach.
SEPC Credit Rating Downgraded to 'D' (Default) by CRISIL and Infomerics
SEPC Limited has experienced a severe credit rating downgrade from both CRISIL Ratings and Infomerics Valuation and Rating. Both agencies have moved the company's long-term and short-term bank facilities to a 'D' (Default) rating. Previously, CRISIL had rated the long-term facilities at 'BB+/Negative' and short-term at 'A4+'. This downgrade to 'D' signifies that the company has defaulted on its debt obligations or is expected to do so imminently, reflecting a critical liquidity crisis.
Key Highlights
CRISIL downgraded Long Term Bank Facilities from 'BB+/Negative' to 'D'
CRISIL downgraded Short Term Bank Facilities from 'A4+' to 'D'
Infomerics downgraded Long Term Bank Facilities from 'BB+/Negative' to 'IVR D'
Infomerics downgraded Short Term Bank Facilities from 'IVR 4+' to 'IVR D'
💼 Action for Investors
Investors should exercise extreme caution as a 'D' rating indicates a default on financial obligations, which typically leads to significant stock price volatility and potential insolvency risks. It is advisable to evaluate the company's debt restructuring plans and liquidity position before maintaining any exposure.
ICRA Places Fino Payments Bank Ratings on Watch Following MD & CEO Arrest
ICRA has placed Fino Payments Bank's ratings of [ICRA]BBB+ and [ICRA]A2+ on 'Watch with Developing Implications'. This rating action follows the arrest of the bank's Managing Director & CEO, Mr. Rishi Gupta, which was initially disclosed on February 27, 2026. The watch applies to fund-based overdraft facilities totaling Rs. 294.54 crore. While the ratings remain unchanged for now, the developing implications status reflects uncertainty regarding management stability and potential operational impacts.
Key Highlights
ICRA places [ICRA]BBB+ and [ICRA]A2+ ratings on 'Watch with Developing Implications'
The rating action affects a total fund-based overdraft limit of Rs. 294.54 crore
Triggered by the arrest of MD & CEO Mr. Rishi Gupta as reported in late February 2026
Major bank limits include Rs. 80 crore with ICICI Bank and Rs. 73.44 crore with State Bank of India
Mr. Ketan Merchant has been identified as the Interim CEO to oversee current operations
💼 Action for Investors
Investors should exercise caution and closely monitor further updates regarding the legal proceedings of the former CEO and the bank's management transition. The 'Watch' status indicates a potential for future rating volatility which could impact the bank's cost of funds and institutional reputation.
iValue Infosolutions Outlines AI Strategy; India AI Mission Deploys 38,000+ GPUs
iValue Infosolutions held a strategic business update call to discuss the impact of AI on its IT infrastructure and cybersecurity operations. Management highlighted the India AI Mission's deployment of over 38,000 GPUs and the registration of 2,300+ startups as significant growth catalysts for the ecosystem. The company is positioning itself as an integrator to manage the 400 million terabytes of data generated daily across sectors like BFSI and Healthcare. iValue aims to address the complexities of 'Shadow AI' and governance as enterprises transition to Generative AI models.
Key Highlights
India AI Mission has deployed 38,000+ GPUs to support sovereign compute and data center expansion.
Over 2,300 startups are registered under the India AI Mission, driving demand for AI-integrated solutions.
Global data generation has reached 400 million terabytes daily, increasing the need for AI-driven analysis.
BFSI sector identified as high-impact with banks running 700-800 applications that require AI for fraud detection.
Company focusing on AI governance to mitigate risks from 'Shadow AI' where employees use ungoverned public AI tools.
💼 Action for Investors
Investors should view this as a positive long-term strategic positioning in the high-growth AI infrastructure and cybersecurity space. Monitor the company's ability to secure contracts within the expanding 38,000+ GPU data center ecosystem in India.
Capri Global Capital Board Approves ₹2,000 Crore Fundraise via Public Issue of NCDs
Capri Global Capital Limited (CGCL) has received board approval to raise up to ₹2,000 crore through the public issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs). The fundraise will be conducted in one or more tranches with a face value of ₹1,000 per debenture. While the total shelf limit is set, specific terms such as coupon rates, tenure, and security details are yet to be finalized. This capital infusion is intended to support the company's lending operations and growth objectives.
Key Highlights
Board approved a total fundraise of up to ₹2,000 crore through NCDs
Proposed issuance of up to 2,00,00,000 NCDs with a face value of ₹1,000 each
The securities will be secured, rated, and listed on the BSE Limited
Fundraising will occur in one or more tranches with terms to be finalized in the future
💼 Action for Investors
Investors should monitor the upcoming announcements regarding the specific coupon rates and credit ratings of these NCDs to assess the company's cost of capital. A successful fundraise will provide necessary liquidity for CGCL to expand its loan book in the MSME and housing finance sectors.
Capri Global Capital Board Approves ₹2,000 Crore Fundraise via Public Issue of NCDs
Capri Global Capital Limited (CGCL) has received board approval to raise up to ₹2,000 crore through the public issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs). The issuance will comprise up to 2 crore NCDs with a face value of ₹1,000 each, to be issued in one or more tranches. While specific terms such as coupon rates and tenure are yet to be finalized, the capital is intended to bolster the company's lending capacity. This move reflects the company's strategy to diversify its funding sources and support long-term growth.
Key Highlights
Approved fundraise of up to ₹2,000 crore through a public issue of NCDs
Issuance of up to 2,00,00,000 NCDs with a face value of ₹1,000 each
Securities will be Secured, Rated, and listed on the BSE Limited
Fundraising to be executed in one or more tranches based on market conditions
Specific terms including coupon rate and tenure to be finalized in subsequent meetings
💼 Action for Investors
Investors should monitor the credit rating and coupon rates once finalized to assess the company's cost of borrowing and financial health. The fundraise is a positive signal for growth, but the impact on margins will depend on the final interest rates offered.
Imagicaaworld to Launch India's First 10,000 Sq. Ft. Hello Park in Hyderabad
Imagicaaworld Entertainment's subsidiary, Imagicaa Next, has signed a Letter of Intent to launch India's first 'Hello Park' at Lake Shore Y Junction Mall in Hyderabad. The 10,000 sq. ft. indoor facility is designed for children aged 3-12 and is expected to open before the 2026 year-end festive season. This move marks the company's entry into the low-capex indoor entertainment segment, aiming to diversify its portfolio beyond large-scale outdoor theme parks. The location is strategic, situated in a 1.6 million sq. ft. mall with high footfall in a dense residential catchment.
Key Highlights
Launching India's first Hello Park in Hyderabad, spanning approximately 10,000 square feet.
Strategically located in Lake Shore Y Junction Mall, a 1.6 million sq. ft. retail hub opened in Dec 2025.
Target opening set before the 2026 year-end festive season to capture peak holiday demand.
New low-capex format focused on children aged 3-12, blending physical play with digital interactivity.
Expansion strategy includes rolling out multiple parks across key urban markets in India.
💼 Action for Investors
Investors should monitor the successful launch and footfall of this first indoor park as it represents a new, scalable, low-capex growth lever for the company. This diversification could lead to more stable year-round revenue compared to seasonal outdoor parks.
Dr. Reddy's Announces Senior Management Reshuffle; M V Ramana Named CEO of Global Generics
Dr. Reddy's Laboratories has announced a significant restructuring of its senior leadership team effective April 1, 2026. Mr. M S Madhu Sundar, who has 28 years of industrial experience, has been elevated to Global Head of Quality and Pharmacovigilance. Key executive roles have been redefined, including M V Ramana as CEO of Global Generics and Sanjay Sharma as Chief Operating Officer. This reshuffle appears to be a strategic move to streamline global manufacturing, quality, and product development operations.
Key Highlights
Mr. M S Madhu Sundar elevated to Global Head of Quality and PV, leveraging 28 years of industry expertise.
Mr. M V Ramana appointed as CEO of Global Generics, a core business segment for the company.
Mr. Sanjay Sharma designated as Chief Operating Officer (COO) effective April 1, 2026.
New leadership appointments made for Integrated Product Development (IPDO) and Consumer Health Organization.
💼 Action for Investors
Investors should monitor the transition of these leaders into their new roles, particularly focusing on the execution of the Global Generics strategy. No immediate portfolio changes are recommended as these are internal elevations and planned role transitions.
Sical Logistics Completes Rights Issue Subscription Period; Closed on March 10, 2026
Sical Logistics Limited has successfully concluded the subscription period for its rights issue on March 10, 2026. The issue, involving equity shares with a face value of Rs. 10, was open for subscription starting February 26, 2026. This capital-raising initiative was previously approved by the Board in meetings held throughout January and February 2026. The company will now move toward the allotment and listing of the new equity shares.
Key Highlights
Rights issue subscription period closed on March 10, 2026, at 5:00 p.m. IST.
The issue was open for a total of 13 days, having commenced on February 26, 2026.
Equity shares offered in the rights issue carry a face value of Rs. 10 per share.
The fundraise follows board approvals dated January 23, February 12, and February 13, 2026.
💼 Action for Investors
Investors should monitor the basis of allotment and the subsequent listing of the new shares on the exchanges. Evaluate the impact of the capital infusion on the company's leverage and future expansion plans.
Metropolis Healthcare Sets March 20 as Record Date for 3:1 Bonus Issue
Metropolis Healthcare Limited has finalized March 20, 2026, as the record date for its 3:1 bonus share issuance. Shareholders holding the stock on this date will be eligible to receive three additional fully paid-up equity shares for every one share they currently own. This corporate action follows the board's recommendation in February 2026 and recent shareholder approval. The deemed date for the allotment of these new shares is scheduled for March 23, 2026.
Key Highlights
Bonus issue ratio confirmed at 3:1 (3 new shares for every 1 existing share)
Record date for eligibility fixed as Friday, March 20, 2026
Deemed date of allotment for bonus shares is Monday, March 23, 2026
Face value of shares remains unchanged at INR 2 per equity share
💼 Action for Investors
Existing shareholders should hold their positions through the record date to qualify for the bonus; note that the share price will adjust downward proportionally on the ex-date. Potential investors should monitor the ex-date to understand the impact on liquidity and price per share.